Takeaways: Alberta’s coverage broadens Elidel’s public-access footprint in Canada and should make it easier for dermatologists to use a non-corticosteroid topical when conventional therapies are...
Takeaways: Rhapsido gives Canadian clinicians a first-in-class, oral BTK inhibitor option for CSU patients who are still symptomatic on H1 antihistamines, adding a targeted,...
CDA-AMC recommends public reimbursement of LEQEMBI (lecanemab) for early Alzheimer’s disease Eisai Canada announced that Canada’s Drug Agency (CDA-AMC) has issued a positive recommendation...
Takeaways: GSK’s prefilled Shingrix syringe should improve operational convenience for clinics and pharmacies by removing the reconstitution step, which can reduce preparation time, ha...
Takeaways: Health Canada’s go‑ahead for Devonian’s seamless Phase II/III pediatric Thykamine program positions the company to enter a crowded but fast‑growing non‑steroidal topica...
Takeaways: Leqembi’s positive reimbursement step in Canada is a meaningful commercial win because it could unlock public coverage for the first disease-modifying Alzheimer’s therapy in the count...
Takeaways: Septa’s acquisition of CeeNU from Bristol Myers Squibb turns it into a supply‑critical oncology player in Canada, securing an essential chemotherapy that has faced...
Takeaways: The licensing of Alethia CMV gives Meridian a saliva-based, rapid molecular test for congenital CMV that can be deployed in the hours after birth, shifting detection from delayed or i...
Takeaways Médunik Canada’s exclusive distribution of Increlex (mecasermin) with ESTEVE ensures that children and adolescents with severe primary IGF‑1 deficiency in Canada can con...
Takeaways Dexcom G7 15 Day’s Health Canada authorization sets up a step-change in CGM economics and adoption once launched, by extending wear to 15.5 days and offering top-tier accuracy and dire...
